| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Bristol-Baylor Laboratory, Department of Pharmacology, Baylor College of Medicine, Houston, Texas 77030
The human colon, intratumoral subpopulations HCT 116 and HCT 116a were established in chemically defined medium supplemented with transferrin, insulin, epidermal growth factor (EGF), triiodothyronine, hydrocortisone, and sodium selenite. The responsiveness of the adapted cell lines to these growth factors was compared in anchorage-dependent and -independent assays. HCT 116 cells maintained in serum-free conditions were further adapted to growth factor deprivation, and the effects of these polypeptides were determined in anchorage-independent assays.
In monolayer, HCT 116 cells adapted to grow in serum-free medium responded to transferrin but not to EGF or insulin. Similarly adapted HCT 116a cells were, however, insensitive to transferrin addition but manifested a 300 and 500% increase in growth rates with EGF and insulin, respectively. Optimal growth of HCT 116 cells was seen in the presence of insulin and transferrin, while maximum proliferation of HCT 116a cells depended on combined insulin, transferrin, and EGF.
In soft agarose, both HCT 116 and HCT 116a subpopulations showed a stringent requirement for transferrin. No combination of growth factors without transferrin supported colony formation.
These data suggest that (a) these colon tumor subpopulations may be subject to separate growth controls, and (b) there may be an important role for transferrin in anchorage-independent growth and possibly in the maintenance of malignant characteristics.
1 This work was supported by NIH Grants CA34432 and CA38100.
2 To whom requests for reprints should be addressed.
Received 8/ 6/86. Revised 7/ 8/87. Revised 12/31/87. Accepted 2/ 1/88.
This article has been cited by other articles:
![]() |
J. Wang, L. Yang, J. Yang, K. Kuropatwinski, W. Wang, X.-Q. Liu, J. Hauser, and M. G. Brattain Transforming Growth Factor {beta} Induces Apoptosis through Repressing the Phosphoinositide 3-Kinase/AKT/Survivin Pathway in Colon Cancer Cells Cancer Res., May 1, 2008; 68(9): 3152 - 3160. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wang, K. Kuropatwinski, J. Hauser, M. R. Rossi, Y. Zhou, A. Conway, J. L.C. Kan, N. W. Gibson, J. K.V. Willson, J. K. Cowell, et al. Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis Mol. Cancer Ther., March 1, 2007; 6(3): 1143 - 1150. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. P. Hu, S. Venkateswarlu, N. Sergina, G. Howell, P. St. Clair, L. E. Humphrey, W. Li, J. Hauser, E. Zborowska, J. K. V. Willson, et al. Reorganization of ErbB Family and Cell Survival Signaling after Knock-down of ErbB2 in Colon Cancer Cells J. Biol. Chem., July 22, 2005; 280(29): 27383 - 27392. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wang, N. Sergina, T. C. Ko, J. Gong, and M. G. Brattain Autocrine and Exogenous Transforming Growth Factor {beta} Control Cell Cycle Inhibition through Pathways with Different Sensitivity J. Biol. Chem., September 17, 2004; 279(38): 40237 - 40244. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Boyd, H. Wang, H. Avila, N. U. Parikh, H. Kessler, V. Magdolen, and G. E. Gallick Combination of an Src Kinase Inhibitor with a Novel Pharmacological Antagonist of the Urokinase Receptor Diminishes in Vitro Colon Cancer Invasiveness Clin. Cancer Res., February 15, 2004; 10(4): 1545 - 1555. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Awwad, N. Sergina, H. Yang, B. Ziober, J. K. V. Willson, E. Zborowska, L. E. Humphrey, R. Fan, T. C. Ko, M. G. Brattain, et al. The Role of Transforming Growth Factor {alpha} in Determining Growth Factor Independence Cancer Res., August 1, 2003; 63(15): 4731 - 4738. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Sawhney, G.-H. K. Zhou, L. E. Humphrey, P. Ghosh, J. I. Kreisberg, and M. G. Brattain Differences in Sensitivity of Biological Functions Mediated by Epidermal Growth Factor Receptor Activation with Respect to Endogenous and Exogenous Ligands J. Biol. Chem., January 4, 2002; 277(1): 75 - 86. [Abstract] [Full Text] |
||||
![]() |
Y. Takei, K. Kadomatsu, S. Matsuo, H. Itoh, K. Nakazawa, S. Kubota, and T. Muramatsu Antisense Oligodeoxynucleotide Targeted to Midkine, a Heparin-binding Growth Factor, Suppresses Tumorigenicity of Mouse Rectal Carcinoma Cells Cancer Res., December 1, 2001; 61(23): 8486 - 8491. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Lu and G. Serrero Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF cDNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468 PNAS, April 11, 2000; 97(8): 3993 - 3998. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-C. Ye, J. M. Foster, W. Li, J. Liang, E. Zborowska, S. Venkateswarlu, J. Gong, M. G. Brattain, and J. K. V. Willson Contextual Effects of Transforming Growth Factor {beta} on the Tumorigenicity of Human Colon Carcinoma Cells Cancer Res., September 1, 1999; 59(18): 4725 - 4731. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Jiang, H. Yang, J. K. V. Willson, J. Liang, L. E. Humphrey, E. Zborowska, D. Wang, J. Foster, R. Fan, and M. G. Brattain Autocrine Transforming Growth Factor alpha Provides a Growth Advantage to Malignant Cells by Facilitating Re-entry into the Cell Cycle from Suboptimal Growth States J. Biol. Chem., November 20, 1998; 273(47): 31471 - 31479. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Howell, L. E. Humphrey, R. A. Awwad, D. Wang, A. Koterba, B. Periyasamy, J. Yang, W. Li, J. K. V. Willson, B. L. Ziober, et al. Aberrant Regulation of Transforming Growth Factor-alpha during the Establishment of Growth Arrest and Quiescence of Growth Factor Independent Cells J. Biol. Chem., April 10, 1998; 273(15): 9214 - 9223. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Howell, L. E. Humphrey, B. L. Ziober, R. Awwad, B. Periyasamy, A. Koterba, W. Li, J. K. V. Willson, K. Coleman, J. Carboni, et al. Regulation of Transforming Growth Factor alpha Expression in a Growth Factor-Independent Cell Line Mol. Cell. Biol., January 1, 1998; 18(1): 303 - 313. [Abstract] [Full Text] |
||||
![]() |
J. Wang, W. Han, E. Zborowska, J. Liang, X. Wang, J. K.V. Willson, L. Sun, and M. G. Brattain Reduced Expression of Transforming Growth Factor beta Type I Receptor Contributes to the Malignancy of Human Colon Carcinoma Cells J. Biol. Chem., July 19, 1996; 271(29): 17366 - 17371. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wang, L. Sun, L. Myeroff, X. Wang, L. E. Gentry, J. Yang, J. Liang, E. Zborowska, S. Markowitz, J. K. V. Willson, et al. Demonstration That Mutation of the Type II Transforming Growth Factor beta Receptor Inactivates Its Tumor Suppressor Activity in Replication Error-positive Colon Carcinoma Cells J. Biol. Chem., September 15, 1995; 270(37): 22044 - 22049. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wang, G.-h. Zhou, T. M. Birkenmeier, J. Gong, L. Sun, and M. G. Brattain Autocrine Transforming Growth Factor [IMAGE][IMAGE] Modulates the Expression of Integrin [IMAGE][IMAGE][IMAGE][IMAGE] in Human Colon Carcinoma FET Cells J. Biol. Chem., June 9, 1995; 270(23): 14154 - 14159. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |